Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug

Puma Biotechnology (PBYI) shares fell Monday on the surprise disclosure that two drugs, not just one, may be necessary to prevent serious diarrhea from afflicting breast cancer patients treated with its experimental drug neratinib.

A marketing application for neratinib to treat breast cancer is under review by the U.S. Food and Drug Administration. Monday's disclosure that Puma is adding a second drug to its diarrhea prophylaxis protocol for neratinib-treated patients once again raises concern that the drug is too toxic to be approved.

Puma shares fell 27% to $36.85 Monday after a research abstract outlining new neratinib diarrhea safety data was posted in advance of a breast cancer research meeting being held in December.

The abstract describes results from a clinical trial in which Puma is using preventative dosing of the anti-diarrheal medicine loperamide to lower the incidence of serious diarrhea reported in neratinib-treated breast cancer patients. The abstract, however, also discloses a new anti-diarrheal regimen consisting of loperamide and budesonide, a steroid.

Investors reacted negatively to the addition of budesonide because it suggests loperamide alone isn't working well enough.

The rate of grade 3 diarrhea was 27% in neratinib-treated breast cancer patients treated with preventative doses of loperamide. When loperamide and budesonide were used together, the rate of grade 3 diarrhea fell to 12.5%, according to the research abstract.

Grade 3 diarrhea is defined as an increase of seven or more stools per day plus incontinence. Without any preventative treatment, 40% of neratinib-treated breast cancer patients experience grade 3 diarrhea or higher.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Barbie Flexes Her Muscle in Mattel's Q1 Earnings

Barbie Flexes Her Muscle in Mattel's Q1 Earnings

Coke's a Better Stock Buy Than Pepsi on North America Sales
Amazon Crushes First-Quarter Profit Estimates -- Watch TheStreet's Live Analysis

Amazon Crushes First-Quarter Profit Estimates -- Watch TheStreet's Live Analysis

Amazon Shares Near All-Time High on Huge Quarterly Earnings Beat

Amazon Shares Near All-Time High on Huge Quarterly Earnings Beat

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb